MPLT - CIK 0001770069
The table below shows MapLight Therapeutics, Inc.'s income statement line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | - | - |
| Cost of revenue | - | - |
| Gross profit | - | - |
| R&D | $138.35M | $68.52M |
| SG&A | $30.73M | $14.42M |
| Operating income | -$169.08M | -$82.95M |
| Income tax | - | - |
| Net income | -$161.15M | -$77.58M |
| EPS (diluted) | -$18.56 | -$105.38 |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.